Abstract: Silymarin, a mixture of flavonolignan and flavonoid polyphenolic compounds extractable 11 from the milk thistle seed, Silybum marianum, has anti-oxidant, anti-inflammatory, anti-cancer and
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Introduction
Nanotechnology has become an important part of medical science, pharmaceutical and food industry, since it focuses on the development of novel delivery systems to sustain or prolong drug release properties, control human biological systems at the molecular level and improve the from the SIL-loaded lipid emulsion as compared with a SIL propylene glycol solution.
177
To overcome the disadvantage of the administration of large volumes of (micro)emulsions per Among various tested oils such as OA, IPM, Triacetin, the highest value of SIL solubilisation was AUC and Cmax were, respectively, 199.45±56.07 μg h/mL and 31.17±7.56 μg/mL, namely, 4-fold and 6-245 fold higher than those of the correspondent drug aqueous suspension.
246
A SIL-loaded liquid nanoemulsion was formulated by Yang et 
254
In a more recent investigation, SIL enriched nanoemulsions were formulated using different oils 255 such as sunflower, EVO and castor oils, respectively, [45] . SIL solubility in castor oil was 0.668 ± 0.072 256 mg/g whereas in EVO and sunflower oils was rather lower. However, upon addition of Tween 80 in 257 oil (10 mg/g), drug solubility increased up to reach 1-2 mg/g in the three tested oils. Coarse emulsions
258
were first prepared by mixing 200 g oil+SIL with 1 L of aqueous phase and then subjected to HPH,
259
giving rise to final droplet sizes in the range 200-300 nm. Moreover, it was found that the greater the 260 oil susceptibility to oxidation, and thus the formation of oxidation products, the greater the SIL 261 degradation incorporated into nanoemulsions.
262
In another recent study, Nagi et al. 
272
formulation after oral administration were found equal to 28.69±3.28 μg h/mL and 3.25±0.48 μg/mL, 273 respectively, i.e., 1.9-fold and 2.7-fold higher than those of a marketed drug suspension.
274
In a recent study [48] , it was reported that a SIL commercial extract could be completely
275
solubilized at the dosage of 40 mg/mL in a nanoemulsion formulated using 2. 
310
To overcome instability problems that commonly occur in the GIT and improve the poor 
319
In order to improve the stability of liposomal nanocarriers and enhance the SIL encapsulation,
320
Xiao et al.
[53] adopted the strategy of "proliposomes", which are defined as dry, solid particles that 321 form a reconstituted liposomal suspension when put in contact with water [54] . The SIL-
322
proliposomes were prepared by film-deposition using mannitol as carrier and a mixture of methanol
323
and chloroform (2:1 v/v) as the apolar medium to dissolve SIL and phospholipids. The content of SIL 324 in the proliposomes was 9.73 % (w/w). In the reconstituted liposomal suspension, the mean particle 
367
Beside to enhance the SIL bioavailability, the liposomal formulation developed by Kumar et al.
368
[59], was designed to promote the regeneration of hepatocytes and to prevent inflammation in liver.
369
The drug entrapment efficiency of liposomes prepared with the TFD technique, was found to be 
375
A slightly different approach was explored by Angelico et al. [60] in the preparation of liposomes 376 loaded with SIL-phytosome rather than using the commercial purified SIL extract in the formulation.
377
The phytosome unit is a molecular complex between phospholipids and standardized polyphenolic 378 
424
In an earlier study, SIL-loaded SLNs were developed using the emulsifiers Compritol 888 ATO,
425
soybean lecithin and poloxamer 188 and both hot and cold variants of the HPH method were 426 compared each other to check differences in drug incorporation modes and release mechanisms [72] .
427
From the analysis of results obtained by centrifugal ultrafiltration method, the SIL encapsulation and solid nanodispersions. Altogether they represent a very efficient strategy by which a poorly water-soluble drug can be dispersed into an inert hydrophilic polymer matrix. As the polymeric erosion progresses, the loaded drug is released in the form of very fine particles for rapid dissolution.
498

Inclusion in polymeric matrices
499 500
The choice of the formulation method is fundamental to optimize the performance of the final 501 product as described by Sonali et al. [82] , who compared kneading, spray drying and co-precipitation 502 techniques in the preparation of SIL-loaded solid dispersions using HPMC as a hydrophilic 503 polymeric carrier. In vitro studies suggested the following enhancement in SIL dissolution compared 504 to pure drug: co-precipitation (2.5 fold) > spray drying (1.9 fold) > kneading (1.5 fold).
505
A novel SIL-based formulation for the treatment of atopic dermatitis (AD) was designed by 506 using pluronic-lecithin organogels, owing to their biphasic composition and versatility as 507 transdermal and topical drug delivery systems [83] . The tested formulations contained 20% oil phase
508
(lecithin / IPM) and 80% aqueous phase (pluronic). The high penetrating ability and hydration effect 509 of the organogel base, provided a significant improvement in the signs and symptoms of AD patients.
510
Nguyen et al.
[84] developed a high-payload supersaturating delivery system by preparing SIL-
511
chitosan nanoparticles from a drug-polysaccharide complexation (nanoplex). At the optimal pH and 512 chitosan-to-SIL charge ratio, the size and zeta potential of nanoplex were, respectively, 243 nm and 
528
were tested to evaluate their capacity as SIL carriers in enhancing the aqueous solubility of the drug.
529
PVP and Tween 80 provided the highest drug solubility of about 800 mg/ml and 2500 mg/ml, 
580
Increase in polymer content led also to delayed drug release due to increase in particle size. Both in 581 vitro and in vivo tests suggested that the developed SIL NP formulation may be useful in the treatment 582 of cirrhosis and fibrosis diseases.
583
Among various methods used in the preparation of chitosan nanoparticles, namely, 584 microemulsion, emulsification/solvent diffusion, polyelectrolyte complex and ionic gelation, the 585 latter was chosen by Pooja et al. [96] , to prepare chitosan-TPP nanoparticles for oral delivery and to 586 evaluate the potential of encapsulated SIL for anticancer activity. In this method, chitosan was 
592
Cytotoxicity studies, revealed that SIL entrapped in chitosan NPs was more effective than free drug.
593
In a different study, SIL NPs were prepared by Snima et al.
[97] through ESE method using
594
PLGA as polymeric nanocarrier. 
677
terminal amino groups on the particle surface. The average particle size was about 18 nm with SIL 678 entrapment efficiency of 95%. In vitro studies revealed a sustained drug release pattern.
679
Another interesting nanohybrid systems containing stimuli-sensitive components was reported 
750
HP-β-CD and RAMEB were developed in order to improve SIL anti-fibrotic activity at a lower 751 therapeutical dose of 50 mg/kg, by increasing their potential solubilization and to prevent their metabolic degradation within the GIT after oral administration, [127] .
Conclusion and outlook
756
The appearance of increasingly advanced and performing Silymarin-based formulations has 757 logically followed step by step the evolution of the nanotechnologies and nanosystems applied to the 758 delivery of poorly water-insoluble drugs and active principle ingredients. In the emulsion solvent evaporation method for oral delivery with high antioxidant activities, bioavailability, and
